SOURCE: Novo Nordisk A/S

February 16, 2009 08:35 ET

Transaction in Own Shares

BAGSVÆRD, DENMARK--(Marketwire - February 16, 2009) - Novo Nordisk A/S - Share repurchase programme


On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 9 February 2009, the following transactions have been made under the programme:

                  Number of    Average     Transaction
                   shares   purchase price value, DKK
Accumulated, last
announcement        537,500                165,995,650
9 February 2009      75,000         302.71  22,703,250
10 February 2009     75,000         305.47  22,910,250
11 February 2009     75,000         301.88  22,641,000
12 February 2009     75,000         305.38  22,903,500
13 February 2009     75,000         311.55  23,366,250
Accumulated under
the programme       912,500                280,519,900

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 200,196 B shares in the period from 9 February 2009 to 12 February 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 25,716,935 treasury shares, corresponding to 4.1% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.


Company Announcement no 9 / 2009


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Further information:

    Media:

    Outside North America:
    Elin K Hansen
    Tel: (+45) 4442 3450
    Email Contact

    Investors:

    Outside North America:
    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Kasper Roseeuw Poulsen
    Tel: 4442 4471
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact

    In North America:
    Hans Rommer
    Tel: (+1) 609 919 7937
    Email Contact